Advertisement
UK markets open in 2 hours 14 minutes
  • NIKKEI 225

    37,980.74
    +352.26 (+0.94%)
     
  • HANG SENG

    17,626.75
    +342.21 (+1.98%)
     
  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     
  • GOLD FUTURES

    2,347.70
    +5.20 (+0.22%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,407.36
    -13.41 (-0.03%)
     
  • CMC Crypto 200

    1,389.26
    +6.68 (+0.48%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?

Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?

Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.